Developer docs
API playgroundTry for free, no card

Search company profiles

Nattopharma ASA

Full company profile

uuid0006y6h

Namestring
Nattopharma ASA
Legal namestring
Nattopharma ASA
Websiteurl
nattopharma.com
Company typeenum
Private
Founded yearint
2004
Short descriptiontext

Nattopharma ASA was a Norwegian public limited company that researched dietary supplements, functional foods, and beverages. Founded in 2004 in Oslo, it was delisted and its website is now inactive, indicating it no longer operates as an independent entity.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
dietary supplement research, functional food development, nutraceutical formulation, beverage ingredient research, food science research
Industry3 codes
1Health & Wellness (Vitamins, Supplements, OTC) DTC
CodeCRAFACACPrimaryYes
2Dietary/Functional Claim Substantiation (e.g., high-protein, low-sugar, keto, low-FODMAP)
CodeAFALAHAEPrimaryNo
3Functional Shot Production (Wellness/Immunity/Focus Shots)
CodeAFAFAFAIPrimaryNo
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
  • Food And Kindred Products2000
Product category
Nutraceutical Research Services
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nattopharma ASA helps research dietary supplements, functional foods, and beverages. The company provides research services aimed at developing formulations and ingredient applications for manufacturers operating in the nutraceutical and functional food sectors. Its work is positioned as a B2B research offering rather than a consumer-facing product.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Dietary supplement, functional food, and beverage research services
No data
Peers10 records
TypeBroad incumbent
Description

dsm-firmenich (formerly DSM Nutritional Products) is one of the world's largest suppliers of vitamins, carotenoids, and functional food ingredients. It is a broad incumbent peer given Nattopharma's positioning in the vitamins and dietary-supplement ingredient supply chain.

TypeBroad incumbent
Description

ADM's Nutrition segment is a large-scale supplier of plant-based proteins, flavors, and functional ingredients to food, beverage, and supplement manufacturers. It is comparable to Nattopharma as a broad incumbent operating across the same downstream functional-food and beverage customer base.

TypeBroad incumbent
Description

Lonza is a global contract development and manufacturing organization supplying nutritional ingredients and dosage-form solutions to supplement and functional-food brands. It is comparable as a broad incumbent in the research-and-supply chain where Nattopharma participated.

TypeOthers
Description

Novonesis (the combined Novozymes and Chr. Hansen) provides fermentation-based enzymes and microbial ingredients used by nutrition and supplement producers. It is an enabling/ecosystem participant comparable to Nattopharma's underlying fermentation-driven production of Vitamin K2 ingredients.

TypeBroad incumbent
Description

Glanbia Nutritionals supplies premix and ingredient solutions to the global nutrition industry, including functional-food, beverage, and supplement manufacturers. It is comparable to Nattopharma as a broad incumbent serving the same downstream customers with formulated nutrition solutions.

TypeEmerging player
Description

NutraBio is a US-based dietary supplement manufacturer that uses branded specialty ingredients (including vitamin K2) in its finished supplement products. It is comparable as an emerging downstream buyer of K2 and other specialty nutritional ingredients in the same supply chain as Nattopharma.

TypeDirect peer
Description

Gnosis by Lesaffre is a major global supplier of fermented nutritional ingredients including Vitamin K2 (MK-7) under its MenaQ7-aligned product range. It is directly comparable to Nattopharma as a B2B supplier of branded K2 and other fermented vitamin ingredients to supplement and functional-food manufacturers.

TypeBroad incumbent
Description

Frutarom, now part of International Flavors & Fragrances (IFF), supplied natural functional ingredients and flavors to the food, beverage, and nutraceutical industries. It is a broad incumbent peer overlapping with Nattopharma's functional-food and beverage ingredient focus.

TypeDirect peer
Description

Kappa Bioscience is a Norwegian Vitamin K2 (MK-7) ingredient manufacturer and the most direct peer to Nattopharma ASA, having historically operated in the same MenaQ7 / Vitamin K2 category for dietary supplements and functional foods. The two companies shared overlapping customer bases in the global supplement industry.

TypeBroad incumbent
Description

Balchem is a US-listed specialty ingredient company whose Human Nutrition & Health segment includes nutritional ingredient offerings (and which has historically been associated with the K2 ingredient category through its acquisition activity). It is comparable as a broad incumbent in the functional-nutrition ingredient space where Nattopharma operated.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nattopharma ASA

Nutraceutical Research Servicesnattopharma.com

Nattopharma ASA was a Norwegian public limited company that researched dietary supplements, functional foods, and beverages. Founded in 2004 in Oslo, it was delisted and its website is now inactive, indicating it no longer operates as an independent entity.

Nattopharma ASA firmographics

Firmographics
Name
Nattopharma ASA
Legal name
Nattopharma ASA
Website
https://nattopharma.com
Company type
Private
Founded year
2004
Operating status
Closed
Headcount range
11–50 employees
Short description
Nattopharma ASA was a Norwegian public limited company that researched dietary supplements, functional foods, and beverages. Founded in 2004 in Oslo, it was delisted and its website is now inactive, indicating it no longer operates as an independent entity.
Ownership category
akta.pro rank

Nattopharma ASA industry classification

Industry
Product category
Nutraceutical Research Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Food And Kindred Products (2000)
akta.pro primary industry
Health & Wellness (Vitamins, Supplements, OTC) DTC (CRAFACAC)
akta.pro secondary industries
Dietary/Functional Claim Substantiation (e.g., high-protein, low-sugar, keto, low-FODMAP) (AFALAHAE), Functional Shot Production (Wellness/Immunity/Focus Shots) (AFAFAFAI)

Keywords

  • Dietary supplement research
  • Functional food development
  • Nutraceutical formulation
  • Beverage ingredient research
  • Food science research

Where Nattopharma ASA is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Markets served

Nattopharma ASA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Nattopharma ASA product offering

Product offering

Core offering

Nattopharma ASA helps research dietary supplements, functional foods, and beverages. The company provides research services aimed at developing formulations and ingredient applications for manufacturers operating in the nutraceutical and functional food sectors. Its work is positioned as a B2B research offering rather than a consumer-facing product.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dietary supplement, functional food, and beverage research services

Companies that use Nattopharma ASA

Customer profile

Ideal customer profiles1 record

Nattopharma ASA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nattopharma ASA competitors and assessment

Company assessment

Broad incumbents

  • dsm-firmenich: dsm-firmenich (formerly DSM Nutritional Products) is one of the world's largest suppliers of vitamins, carotenoids, and functional food ingredients. It is a broad incumbent peer given Nattopharma's positioning in the vitamins and dietary-supplement ingredient supply chain.
  • ADM Nutrition: ADM's Nutrition segment is a large-scale supplier of plant-based proteins, flavors, and functional ingredients to food, beverage, and supplement manufacturers. It is comparable to Nattopharma as a broad incumbent operating across the same downstream functional-food and beverage customer base.
  • Lonza Capsules & Health Ingredients: Lonza is a global contract development and manufacturing organization supplying nutritional ingredients and dosage-form solutions to supplement and functional-food brands. It is comparable as a broad incumbent in the research-and-supply chain where Nattopharma participated.
  • Glanbia Nutritionals: Glanbia Nutritionals supplies premix and ingredient solutions to the global nutrition industry, including functional-food, beverage, and supplement manufacturers. It is comparable to Nattopharma as a broad incumbent serving the same downstream customers with formulated nutrition solutions.
  • Frutarom (now IFF Health & Bioscience): Frutarom, now part of International Flavors & Fragrances (IFF), supplied natural functional ingredients and flavors to the food, beverage, and nutraceutical industries. It is a broad incumbent peer overlapping with Nattopharma's functional-food and beverage ingredient focus.
  • Balchem Corporation: Balchem is a US-listed specialty ingredient company whose Human Nutrition & Health segment includes nutritional ingredient offerings (and which has historically been associated with the K2 ingredient category through its acquisition activity). It is comparable as a broad incumbent in the functional-nutrition ingredient space where Nattopharma operated.

Others

  • Novozymes (Novonesis): Novonesis (the combined Novozymes and Chr. Hansen) provides fermentation-based enzymes and microbial ingredients used by nutrition and supplement producers. It is an enabling/ecosystem participant comparable to Nattopharma's underlying fermentation-driven production of Vitamin K2 ingredients.

Emerging players

  • NutraBio Labs: NutraBio is a US-based dietary supplement manufacturer that uses branded specialty ingredients (including vitamin K2) in its finished supplement products. It is comparable as an emerging downstream buyer of K2 and other specialty nutritional ingredients in the same supply chain as Nattopharma.

Direct peers

  • Gnosis by Lesaffre: Gnosis by Lesaffre is a major global supplier of fermented nutritional ingredients including Vitamin K2 (MK-7) under its MenaQ7-aligned product range. It is directly comparable to Nattopharma as a B2B supplier of branded K2 and other fermented vitamin ingredients to supplement and functional-food manufacturers.
  • Kappa Bioscience: Kappa Bioscience is a Norwegian Vitamin K2 (MK-7) ingredient manufacturer and the most direct peer to Nattopharma ASA, having historically operated in the same MenaQ7 / Vitamin K2 category for dietary supplements and functional foods. The two companies shared overlapping customer bases in the global supplement industry.

Market position

Customer concentration

Nattopharma ASA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nattopharma ASA leadership team

Management profile

Number of profiles

Profiles2 records

Nattopharma ASA funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nattopharma ASA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nattopharma ASA

What does Nattopharma ASA do?

Nattopharma ASA helps research dietary supplements, functional foods, and beverages. The company provides research services aimed at developing formulations and ingredient applications for manufacturers operating in the nutraceutical and functional food sectors. Its work is positioned as a B2B research offering rather than a consumer-facing product.

Is Nattopharma ASA a public or private company?

Nattopharma ASA is a private company. It is classified as public and is currently closed.

When was Nattopharma ASA founded?

Nattopharma ASA was founded in 2004. It employs 11 to 50 people.

Where is Nattopharma ASA based?

Nattopharma ASA is headquartered in Oslo, Norway, in the Europe region.

Who are Nattopharma ASA's main competitors?

Broad incumbents on record are dsm-firmenich, ADM Nutrition, Lonza Capsules & Health Ingredients, Glanbia Nutritionals, Frutarom (now IFF Health & Bioscience) and Balchem Corporation. Novozymes (Novonesis) is listed as an others. NutraBio Labs is listed as an emerging player. Direct peers are Gnosis by Lesaffre and Kappa Bioscience.

Does Nattopharma ASA have an API?

No public API is recorded for Nattopharma ASA.

What industry is Nattopharma ASA in?

Nattopharma ASA's product category is Nutraceutical Research Services. Its primary akta.pro industry code is CRAFACAC, Health & Wellness (Vitamins, Supplements, OTC) DTC, with a secondary code of AFALAHAE, Dietary/Functional Claim Substantiation (e.g., high-protein, low-sugar, keto, low-FODMAP). Its NAICS code is 5417 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Next FinanceLesaffre poursuit son développement en nutrition et santé humaine avec l’acquisition de NattoPharma, en NorvègeLesaffre has finalized the acquisition of NattoPharma, a Norwegian nutraceutical company specializing in vitamin K2, holding over 90% of its capital. This move strengthens Gnosis by Lesaffre's position in the human nutrition and health market as it prepares to delist NattoPharma from the Oslo stock exchange.LesaffreLesaffre expands its development in human nutrition and health with the acquisition of NattoPharma, in NorwayLesaffre has acquired NattoPharma, a company based in Norway, to expand its development in human nutrition and health. This acquisition marks Lesaffre's strategic move into the Norwegian market for specialized nutritional products.GlobeNewswireNATTO: SHARE CAPITAL INCREASENATTO Pharma registered a share capital increase to NOK 52,709,799, divided into 17,569,933 shares of NOK 3.00 each. The new shares will be listed on the Oslo Stock Exchange once issued, expected by 20 October 2016.GlobeNewswireNattoPharma: 2nd Quarter and first half 2016 earnings releaseNattoPharma reported Q2 2016 revenue of NOK 13.3 million, up 73% year-over-year, with a gross margin of 50.2% and an adjusted EBITDA loss of NOK 0.35 million. For the first half, revenue rose 78% to NOK 25.8 million, with a gross margin of 50.3% and a pre-tax loss of NOK 9.8 million.GlobeNewswireNATTO: SHARE CAPITAL INCREASENATTO Pharma registered a share capital increase to NOK 52,334,799, divided into 17,444,933 registered shares of NOK 3.00 each. The new shares will be admitted to listing on the Oslo Stock Exchange, expected to be completed by September 1, 2016.GlobeNewswireNattoPharma Awarded New Patent for Vitamin K2NattoPharma ASA was awarded a U.S. patent on June 14, 2016, for vitamin K2's cardiovascular benefits, specifically reducing age-related arterial stiffening. The patent covers vitamin K2 with vitamin D in dietary supplements and food products. The company plans to explore growth in supplements, fortified foods, and future pharmaceutical applications.GlobeNewswireNattoPharma: Minutes of Meeting from Ordinary Annual General Meeting held May 20th 2016NattoPharma ASA held its Ordinary Annual General Meeting on May 20, 2016, and published the minutes. The company, based in Norway, is the world's leader in vitamin K2 R&D and the exclusive international supplier of MenaQ7® Vitamin K2. It also established its North American subsidiary, NattoPharma USA, in Metuchen, NJ.GlobeNewswireNattoPharma: 1st Quarter 2016 earnings releaseNattoPharma reported record Q1 2016 revenue of NOK 12.5 million, up 84% year-over-year, with gross margin at 50.4% and EBITDA improving to negative NOK 1.7 million. Cash and cash equivalents rose to NOK 26.7 million, and the company will hold a webcast with its CEO and CFO.GlobeNewswireNattoPharma ASA : Annual Report 2015NattoPharma ASA published its 2015 Annual Report on April 29, 2016, available as a PDF on its website. The report is also downloadable from the company's site, and contact information for the CFO is provided.GlobeNewswireNatto: Release of NattoPharma 's results for Q3 2015NattoPharma released its Q3 2015 results on November 23, 2015, and held a presentation at the KS - Agenda conference center in Oslo on November 25. CEO Hogne Vik presented the results, and the company highlighted its MenaQ7 vitamin K2 product with clinical evidence for bone and cardiovascular health.